Industry

Tenpoint Therapeutics and PHIL Inc. Partner to Launch Yuvezzi Direct-to-Patient Cash Program

Vision Monday7h ago1 min read

SEATTLE—Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., an all-in-one digital hub and direct-to-patient platform, have announced the launch of a direct-to-patient (DTP) cash program for Yuvezzi, the first dual-agent prescription eye drop FDA-approved for the treatment of presbyopia. Tenpoint gained FDA approval for Yuvezzi in January of this year and recently launched the product nationwide. The program delivers Yuvezzi directly to patients through a seamless access experience with affordable, transparent pricing, home delivery, and dedicated support, the announcement said.

Read full article on Vision Monday

AI Summary

Quick Take

Tenpoint Therapeutics has partnered with PHIL Inc. to launch a direct-to-patient cash program for Yuvezzi, the first FDA-approved dual-agent eye drop for presbyopia. This initiative aims to bypass traditional pharmacy hurdles by offering transparent pricing and home delivery for the recently launched nationwide product.

Why It Matters

The presbyopia drop market has faced significant hurdles with insurance coverage and high out-of-pocket costs, often leading to prescription abandonment at the pharmacy counter. By utilizing a direct-to-patient cash model, Tenpoint is attempting to stabilize the patient experience and ensure price predictability, which is critical for elective lifestyle medications. This move reflects a broader industry trend where manufacturers of cash-pay or poorly covered drugs are seeking digital pharmacy partners to streamline the pipeline from prescription to patient.

Key Details

Yuvezzi is the first dual-agent prescription eye drop approved by the FDA specifically for the treatment of presbyopia.
The partnership with PHIL Inc. creates a digital hub that manages the fulfillment process from prescription to home delivery.
The program focuses on a cash-pay model to provide transparent, predictable pricing for patients regardless of insurance status.
Tenpoint Therapeutics received FDA approval for Yuvezzi in January and has now moved into a full nationwide commercial launch.
The platform includes dedicated support services to assist patients throughout the access and delivery process.

Practice Implications

Clinicians prescribing Yuvezzi can now offer patients a streamlined fulfillment path that avoids the variability of retail pharmacy pricing and stock issues. This model may reduce the administrative burden on office staff who typically handle prior authorizations or pharmacy callbacks for non-covered lifestyle medications.

Who's Affected

OptometristsOphthalmologistsPractice OwnersRefractive Surgeons

What's Next

Following the nationwide launch and the implementation of this DTP program, the industry will be watching for patient adoption rates and how this dual-agent formula competes with existing single-agent presbyopia drops. Further updates regarding specific cash pricing tiers and long-term patient retention data are expected as the program matures.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.